Mannkind (MNKD) reported $349M in revenue for fiscal 2025, +22.2% year on year. That ranks #2410 by revenue among 2853 SEC filers and #238 in Healthcare. Net income was $5.9M, a net margin of 1.7%. Revenue has grown 8.0% a year on average since 2016 ($175M then). The fiscal 2025 balance sheet shows $792M in total assets, $74.9M in cash and $355M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $349M | +22.2% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $38.8M | −46.5% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $5.9M | −78.7% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $18.3M | −57.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.6M | −52.9% | FY20252025-12-31 |
| Total assetsAssets | $792M | +101.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$51.0M | +$27.8M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $74.9M | +61.6% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $355M | +883.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $90.2M | −$16.6M | Open → |
| Q2 20262026-06-30 | $109M | −$19.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Mannkind Corp
- Ticker
- MNKD
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000899460
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Pharming GroupPHAR | $376M | $2.9M |
| Arcutis BiotherapeuticsARQT | $376M | −$16.1M |
| InmodeINMD | $370M | $93.8M |
| MannkindMNKD | $349M | $5.9M |
| InogenINGN | $349M | $22.7M |
| Castle BiosciencesCSTL | $344M | −$24.2M |
| Tactile Systems TechnologyTCMD | $330M | $19.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Mannkind — Key figures |url=https://companiesranked.com/en/company/mannkind |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Mannkind — Key figures. CompaniesRanked. https://companiesranked.com/en/company/mannkindBibTeX
@misc{companiesranked-en-company-mannkind-2026,
author = {{CompaniesRanked}},
title = {{Mannkind — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/mannkind}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-073516 · February 26, 2026
{{cite web |title=Mannkind — Key figures — 10-K (0001193125-26-073516) |url=https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.